NDAINJECTIONINJECTABLE
Approved
May 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug Shortage Active
ZANOSAR is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
ZANOSAR (streptozocin) by Teva. Approved for pancreatic cancer. First approved in 1982.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANOSAR (streptozocin) is a nitrosourea alkylating agent approved in 1982 for pancreatic cancer, specifically neuroendocrine tumors. It works by damaging DNA and inhibiting cellular protein synthesis. The drug is administered intravenously and remains a standard-of-care option in a limited but durable patient population.
LOE Approaching
As a legacy product approaching LOE with minimal current market presence, the brand team is likely small and focused on maintaining existing patient relationships rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
Started Aug 2007
1 enrolled
Pancreatic Cancer
Career Relevance
Working on ZANOSAR offers limited career growth but deep expertise in specialty oncology, rare disease management, and legacy product stewardship. This is a niche role ideal for professionals seeking stable, focused work in an established therapeutic area without high-pressure growth targets.
Worked on ZANOSAR at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.